跳至主要内容
临床试验/KCT0002691
KCT0002691已完成未知

Determination of EC95 of remifentanil for smooth emergence from sevoflurane anesthesia in patients undergoing trans-femoral cerebral angiography

Samsung Medical Center0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
20(Year) 至 70(Year)(—)
性别
All

入选标准

  • Adults undergoing TFCA because of cerebrovascular disease ( age from 20 to70 years )
  • ASA class I - III
  • patients who agree to the clinical trial and signs written informed consent

排除标准

  • - Symptoms or signs of increased intracranial pressure
  • - uncontrolled hypertension
  • - preoperative administration of an antitussive agent
  • - patients with gastroesophageal reflux
  • - allergic history with use of remifentanil or contraindication for remifentanil
  • - patients with arrythmia or congestive heart failure (new York heart association heart failure grade 3,4)
  • - Acute or chronic respiratory disease or patients who require ventilator care after Trans-femoral cerebral angiography
  • (Bronchial asthma, chronic obstructive lung disease, upper respiratory infection within 2 weeks etc.)
  • - severe obesity (BMI > 35 kg/m2)
  • - severe obstructive sleep apnea
  • - anticipated difficult airway
  • - A person who does not recover consciousness 20 minutes after discontinuing sevoflurane administration
  • (Consider delayed emergence and exclude the patient from trial)
  • - Patients who are judged to be inadequate to participate in clinical trials at the discretion of the researcher
  • - Patients who do not agree to participate in the study

研究者

相似试验